Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
Provided By GlobeNewswire
Last update: Mar 20, 2025
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025
Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025
Read more at globenewswire.comNASDAQ:ERAS (7/23/2025, 1:21:49 PM)
1.75
+0.07 (+4.17%)
Find more stocks in the Stock Screener
